The stock exchanged hands with 9,322,450 numbers of shares compared to its average daily volume of 4.83M shares. SCMP was included in 3 notes of analysts from September 7, 2016. Analysts reported that the Price Target for Sucampo Pharmaceuticals, Inc. might touch $43 high while the Average Price Target and Low price Target is $21.29 and $11 respectively. Mizuho upgraded the stock to "Buy" rating in Thursday, December 22 report.
The consensus analysts recommendation at this point stands at 2.70 on Sucampo Pharmaceuticals, Inc. Maxim Group lowered shares of Sucampo Pharmaceuticals to a "hold" rating in a research note on Monday, January 1st. Finally, Globeflex Capital L P increased its stake in shares of Sucampo Pharmaceuticals by 0.3% in the second quarter. SCMP's profit will be $15.96 million for 13.51 P/E if the $0.34 EPS becomes a reality.
Among 10 analysts covering Coherus Biosciences (NASDAQ:CHRS), 9 have Buy rating, 0 Sell and 1 Hold. The stock presently has a consensus rating of "Buy" and an average price target of $21.58. (NASDAQ:SCMP). Ativo Capital Management Lc has 0.4% invested in Sucampo Pharmaceuticals, Inc. The company has market cap of $849.64 million. The company has market cap of $223.66 million. The stock, as of last close, traded 97.85% away to its 52 week low and was at a distance of 1.10% from its 52 week high.
Equities researchers at Leerink Swann raised their FY2019 earnings per share estimates for shares of Sucampo Pharmaceuticals in a research note issued on Monday, Zacks Investment Research reports. After $-0.68 actual earnings per share reported by Syndax Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 36.76% negative EPS growth. The company's net profit margin has achieved the current level of -60.2 percent and possesses 72.8 percent gross margin. The business had revenue of $61.27 million during the quarter, compared to analysts' expectations of $58.05 million. The low EPS estimate is $0.25, while the high EPS estimate is $0.36. The company reported the earnings of $0.27/Share in the last quarter where the estimated EPS by analysts was $0.25/share.
In other Sucampo Pharmaceuticals news, insider Peter A. Kiener sold 50,000 shares of the stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $16.86, for a total transaction of $337,200.00. SCMP's SI was 4.69 million shares in January as released by FINRA. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Arizona State Retirement System grew its position in Sucampo Pharmaceuticals by 1.6% during the second quarter. Rhumbline Advisers raised its holdings in shares of Sucampo Pharmaceuticals by 0.9% in the second quarter.
The stock decreased 1.63% or $0.3 during the last trading session, reaching $18.1. UBS downgraded Sucampo Pharmaceuticals, Inc. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company's stock valued at $126,000 after purchasing an additional 631 shares during the last quarter. Vanguard Group Inc. now owns 1,646,348 shares of the biopharmaceutical company's stock valued at $17,287,000 after buying an additional 189,561 shares in the last quarter. The Manufacturers Life Insurance Company now owns 19,983 shares of the biopharmaceutical company's stock valued at $209,000 after buying an additional 790 shares during the period. Rhumbline Advisers now owns 48,810 shares of the biopharmaceutical company's stock valued at $513,000 after buying an additional 423 shares during the period. Company insiders own 3.31% of the company's stock. If you are accessing this report on another site, it was stolen and reposted in violation of global copyright & trademark law. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & worldwide copyright legislation. The original version of this report can be read at [[permalink]].
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company's product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders.